Literature DB >> 2961563

Heterogeneity of insulin-like growth factor binding proteins and relationships between structure and affinity. 1. Circulating forms in man.

S Hardouin1, P Hossenlopp, B Segovia, D Seurin, G Portolan, C Lassarre, M Binoux.   

Abstract

Circulating insulin-like growth factors (IGFs) are bound to specific, high-affinity binding proteins (BPs), and form complexes with relative molecular masses of about 150,000 ('large' complex) and 40,000 ('small' complex). The large complex appears to be under growth-hormone control and its proportions vary with those of the IGFs. Molecular heterogeneity among the binding proteins was revealed by polyacrylamide gel electrophoresis (SDS-PAGE) of serum in which they were cross-linked to 125I-labelled IGF I or II. Out of the six specific bands observed, of 150,000, 120,000, 49,000, 40,000 and 37,000 Mr, the last three appeared in both complexes, whereas the first three were visible only in the large complex. Some or all of the 49,000-37,000-Mr species may constitute the subunits of 150,000-Mr and/or 120,000-Mr IGF-BP complexes. With electrophoresis followed by transfer onto nitrocellulose and incubation with either 125I-labelled IGF I or II (western blot), the different binding proteins were identified per se. There were five molecular forms with Mr of 41,500, 38,500, 34,000, 30,000 and 24,000. In normal serum the 41,500 and 38,500-Mr forms were the major binding proteins. They appeared in both complexes, but were predominant in the large complex where they constitute the elementary binding units. These two proteins therefore bind to IGFs to form both 'monomeric' IGF-BP and 'oligomeric' (IGF-BP)n complexes. The 34,000, 30,000 and 24,000-Mr forms, by contrast, were visible only in the small complex. Different mechanisms appear to regulate the different binding proteins: in acromegalic serum the 41,500 and 38,500-Mr forms were augmented and the 34,000-Mr form diminished, whereas in hypopituitary serum the reverse was true and, in addition, the 30,000-Mr form was augmented. With chromatofocusing, the 34,000, 30,000 and 24,000-Mr forms eluted in three peaks between pH 6.0 and 4.0, whereas the 41,500 and 38,500-Mr forms eluted throughout the gradient, principally at pH 7.5 and 7.0. Competitive binding studies, done on binding proteins separated either by chromatofocusing or by SDS-PAGE and transfer onto nitrocellulose, revealed different affinities for the IGFs among the different molecular forms. The 41,500 and 24,000-Mr binding proteins preferentially bound IGF I and the 38,500, 34,000 and 30,000-Mr proteins preferentially bound IGF II. Our findings demonstrate the molecular heterogeneity of the binding proteins and the existence of a relationship between their structure and their affinities for the IGFs.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2961563     DOI: 10.1111/j.1432-1033.1987.tb13676.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  20 in total

Review 1.  Disturbance of growth hormone--insulin-like growth factor axis in uraemia. Implications for recombinant human growth hormone treatment.

Authors:  B Tönshoff; F Schaefer; O Mehls
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

2.  Different indices of fetal growth predict bone size and volumetric density at 4 years of age.

Authors:  Nicholas C Harvey; Pamela A Mahon; Sian M Robinson; Corrine E Nisbet; M Kassim Javaid; Sarah R Crozier; Hazel M Inskip; Keith M Godfrey; Nigel K Arden; Elaine M Dennison; Cyrus Cooper
Journal:  J Bone Miner Res       Date:  2010-04       Impact factor: 6.741

Review 3.  Somatomedin-binding proteins: what role do they play in the growth process?

Authors:  S Cianfarani; J M Holly
Journal:  Eur J Pediatr       Date:  1989-11       Impact factor: 3.183

4.  Structure of the Mr 140,000 growth hormone-dependent insulin-like growth factor binding protein complex: determination by reconstitution and affinity-labeling.

Authors:  R C Baxter; J L Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

5.  Insulin-like growth factor binding proteins from cultured human fibroblasts. Characterization and hormonal regulation.

Authors:  C A Conover; F Liu; D Powell; R G Rosenfeld; R L Hintz
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

6.  Decrease in the glycosaminoglycan content in the skin of diabetic rats. The role of IGF-I, IGF-binding proteins and proteolytic activity.

Authors:  M Cechowska-Pasko; J Pałka; E Bańkowski
Journal:  Mol Cell Biochem       Date:  1996-01-12       Impact factor: 3.396

7.  Insulin-like growth factor-I (IGF-I) and IGF-binding proteins blood serum levels in women with early- and late-stage breast cancer: mutual relationship and possible correlations with patients' hormonal status.

Authors:  R E Favoni; A de Cupis; A Perrotta; S Sforzini; D Amoroso; F Pensa; L Miglietta
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

8.  Translocation between chromosomes 6 and 15 (45,XX,t(6;15)(q25;q11.2)) with further evidence for lack of imprinting of the insulin-like growth factor II/mannose-6-phosphate receptor in humans.

Authors:  E Treacy; C Polychronakos; M Vekemans; P Eydoux; S Blaichman; H Scarpelli; M Ross; Y Xu; V M Der Kaloustian
Journal:  J Med Genet       Date:  1996-01       Impact factor: 6.318

9.  Colonic absorption of insulin-like growth factor I in vitro.

Authors:  E Quadros; N M Landzert; S LeRoy; F Gasparini; G Worosila
Journal:  Pharm Res       Date:  1994-02       Impact factor: 4.200

10.  Expression and regulation of insulin-like growth factor binding protein-1 in the rat uterus throughout estrous cycle.

Authors:  A Ghahary; J Luo; L J Murphy
Journal:  Mol Cell Biochem       Date:  1993-07-07       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.